NUAgo Therapeutics

📍 Chicago, United States🗓 Founded 2020👥 4 employees💰 Last funded Aug 2024
Biotechnology Research🌐 nuagotherapeutics.com
Website LinkedIn
NUAgo Therapeutics is redefining the precision approach in cancer therapeutics. We are a pre-clinical stage company developing single-construct short RNAs that target dozens of critical cancer essential genes in systemic delivery platform that kill tumors specifically without observed toxicity in normal tissues. No longer bound to the treatment restrictions imposed due to patient and tumor heterogeneity, NUAgos short RNAs offer the promise shift to potentially shift cancer therapy toward a chronic-like condition with periods of complete response or tumor elimination. Reach out to us if you would like to learn more.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in NUAgo Therapeutics?
NUAgo Therapeutics has 1 investors on record on gritt.io, 1 mid-stage.
When did NUAgo Therapeutics last raise funding?
The most recent investment in NUAgo Therapeutics recorded on gritt.io was in August 2024.
When was NUAgo Therapeutics founded?
NUAgo Therapeutics was founded in 2020.
What industry is NUAgo Therapeutics in?
NUAgo Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is NUAgo Therapeutics based?
NUAgo Therapeutics is headquartered in Chicago, United States.